SEC Form 4 · accession 0001209191-18-061404

GENOMIC HEALTH INC · GHDX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Scientific Officer

Period of report

Dec 3, 2018

Accepted (ET)

Dec 6, 2018 · 7:47 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001131324

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Dec 3, 2018	M	1,500	$17.33	A	338,241	D
Common Stock^F2,F3,F4,F1	Dec 3, 2018	S	113	$76.2758	D	338,128	D
Common Stock^F2,F3,F5,F1	Dec 3, 2018	S	1,087	$77.9347	D	337,041	D
Common Stock^F2,F6,F1	Dec 3, 2018	S	100	$78.60	D	336,941	D
Common Stock^F2,F3,F7,F1	Dec 3, 2018	S	200	$80.395	D	336,741	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F8	$17.33	Dec 3, 2018	M	1,500	D	—	Dec 4, 2018	Common Stock	1,500	0	D

F1Includes an aggregate of 13,320 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
F2These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on March 9, 2018.
F3Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
F4Represents weighted average sale price. Actual sale prices ranged from $76.27 to $76.32.
F5Represents weighted average sale price. Actual sale prices ranged from $77.32 to $78.26.
F6Represents actual sale price.
F7Represents weighted average sale price. Actual sale prices ranged from $80.05 to $80.74.
F8The option became exercisable as to 25% of the shares on December 4, 2009, and became exercisable as to 1/48th of the shares each full month thereafter.